Genitourinary Cancer

Apalutamide Induces Impressive PSA Response and Solid Adherence Rates in Men with nmCRPC

September 23, 2021

Real-world evidence recently presented at the 2021 AUA Annual Meeting showed that high adherence rates and favorable prostate-specific antigen (PSA) response were observed in men with nmCRPC who were treated with apalutamide.

Darolutamide Postpones Need For Procedure, Slows Down Quality of Life Deterioration in Patients with nmCRPC

September 13, 2021

Researchers identified a slower rate of health-related quality of life deterioration, as well as an ability to postpone locally invasive procedures, in patients with nonmetastatic castration-resistant prostate cancer who received darolutamide.